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Objective: Despite increased public awareness and use of opioid
agonist therapy (OAT), there is little published data on contraception
among women on methadone or buprenorphine/naloxone. This
study aimed to characterize patterns of contraception use among
this population.
Methods:We conducted a cross-sectional survey between May 2014
and October 2015 at 6 medical clinics, pharmacies, and community
organizations in British Columbia. Trained surveyors used the
Canadian Sexual Health Survey (CSHS) to collect information on
contraceptive practices and barriers to health care access.
Descriptive analysis was performed on the subset of women on
OATwho were at risk for unintended pregnancy.
Results: Of the 133 survey respondents, 80 (60.2%) were at risk for
unintended pregnancy. Among the 46 respondents with a recent
pregnancy, 44 (95.7%) reported it as unintended. Of those at risk for
unintended pregnancy, the most common contraceptive methods
used were “no method,”male condom, and depo-
medroxyprogesterone at 28.8%, 16.3%, and 12.5%, respectively.
Only 5% reported dual protection with a barrier and hormonal or
intrauterine method. Barriers to contraception access included
difficulty booking appointments with providers and cost, although
97% of all respondents reported feeling comfortable speaking with a
physician about contraception.
Conclusion:We found that most respondents using OAT reported prior
pregnancies that were unintended, and used less effectivecontraceptive methods. Health care professionals who provide
addiction care are uniquely positioned to address their patients’
concerns about contraception. Incorporating family planning
discussions into OATservices may improve understanding and use of
effective contraceptive methods. Addressing unmet contraceptive
needs may enable women on OAT to achieve their reproductive goals.Résumé
Objectif : En depit de la sensibilisation accrue du public et de
l’augmentation du recours au traitement par agonistes opioïdes
(TAO), il existe peu de donnees publiees sur la contraception chez
les femmes qui suivent un traitement par methadone ou
buprenorphine-naloxone. Cette etude visait a caracteriser les
habitudes contraceptives de cette population.
Méthodologie : Nous avons mene une enquête transversale entre
mai 2014 et octobre 2015 dans 6 cliniques medicales, pharmacies
et organismes communautaires de la Colombie-Britannique. Des
enquêteurs qualifies ont utilise l’enquête canadienne sur la sante
sexuelle (Canadian Sexual Health Survey) pour recueillir des
donnees sur les methodes contraceptives et les obstacles a l'acces
aux soins de sante. Une analyse descriptive a ete effectuee sur le
sous-groupe de femmes suivant un TAO qui presentaient un risque
de grossesse imprevue.
Résultats : Parmi les 133 repondantes, 80 (60,2 %) etaient a risque de
grossesse imprevue. Parmi les 46 repondantes ayant recemment
ete enceintes, 44 (95,7 %) ont declare qu’il s’agissait d’une
grossesse imprevue. Chez les femmes a risque de grosse
imprevue, les methodes contraceptives les plus utilisees etaient
« aucune methode » (28,8 %), le condom masculin (16,3 %) et
l’acetate de medroxyprogesterone (12,5 %). Seulement 5 % ont
signale une double protection avec une methode de type barriere et
un contraceptif hormonal ou un sterilet. Les obstacles a l'acces a la
contraception comprenaient la difficulte a fixer des rendez-vous
avec les fournisseurs de soins et les coûts, bien que 97 % de toutes
les repondantes aient indique être a l’aise de parler de
contraception avec un medecin.
Conclusion : Nous avons constate que la plupart des repondantes
suivant un TAO ont signale des grossesses imprevues anterieures
et utilisaient les methodes contraceptives les moins efficaces. Les
professionnels de la sante qui offrent des soins en matiere de
dependance sont dans une position ideale pour repondre aux
inquietudes de leurs patientes sur la contraception. L’integration
des discussions sur la planification familiale dans les services de
TAO peut aider les patientes a comprendre et a utiliser des
methodes contraceptives efficaces. Le fait de repondre a ces000 JOGC 000 2020  1
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besoins contraceptifs non satisfaits pourrait outiller les femmes
suivant un TAO de sorte qu’elles puissent atteindre leurs objectifs
de planification familiale.© 2020 The Society of Obstetricians and Gynaecologists of Canada/La
Société des obstétriciens et gynécologues du Canada. Published by
Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
J Obstet Gynaecol Can 2020;000(000):1−7
https://doi.org/10.1016/j.jogc.2020.06.027
INTRODUCTION
There is a paucity of published data on the contracep-tion practices of women on opioid agonist therapies
(OATs) in Canada. Two studies from Australia indicate
poor uptake of contraception and high rates of unintended
pregnancy among women enrolled in drug treatment pro-
grams.1,2 Reasons cited by patients include perceived infer-
tility, menstrual irregularities, inaccessibility of care, and
direct effects of illicit drug use.2 Other barriers include the
stigma of being labelled an addict, guilt, and fear of judge-
ment.1,2 We were unable to find Canadian studies looking
at these barriers.
Substance dependence is increasingly recognized as a com-
plex neurobiological disorder characterized by physiologi-
cal tolerance, psychological cravings, and withdrawal that
significantly affect overall function.3 Recently, public
awareness of opioid addiction has dramatically increased
owing to opioid-associated overdose and death in Canada.4
First-line pharmacological therapies for substance use dis-
order include methadone (MET) and buprenorphine/nal-
oxone (BUP). Both medications serve as OATs that bind
to mu-opioid receptors to attenuate withdrawal symp-
toms.5 MET has been shown to decrease use of illicit
drugs, sexually transmitted infections, and mortality and to
increase treatment retention and employment.6
It is estimated that in British Columbia, over 15 000 and
6 000 patients, respectively, are on MET and BUP as opi-
oid agonist therapy.7 Although women account for approx-
imately 30% to 45% of OAT patients, reproductive health
is not routinely addressed by their care providers.8,9 Web-
ster et al.10 and Black et al. found that sexually active
women receiving substance dependence treatment were
more likely to have a history of poor reproductive health
outcomes, unplanned pregnancies, and noncompliant con-
traception use.1 Data from Bornstein et al. suggest a higher
rate of unintended pregnancy and lower rate of contracep-
tion use among women on MET, despite mixed feelings
about pregnancy among these women.11 These outcomes 000 JOGC 000 2020may be due to the relapsing-remitting nature of substance
addiction, poor socioeconomic status, and barriers to
health care access.
To better understand the facilitators of and barriers to con-
traception use among Canadian women who use OAT, and
to support evidence-informed policies and programs that
identify and support those with unmet needs for contra-
ception to equitably access sexual health services, we
planned a survey study among women on MET or BUP in
British Columbia.METHODS
We conducted a cross-sectional survey between May 2014
and October 2015 using the Canadian Sexual Health Sur-
vey.12 This tool is based on similar validated national
(Canadian Community Health Survey) and international
(National Survey of Family Growth) surveys and has been
piloted and validated among BC populations.12−14 We
invited a range of pharmacies, medical clinics, and commu-
nity organizations providing service to women on OAT to
participate as recruiting sites. Six sites located in three of
the five BC health authority regions agreed to participate.
Posters introducing the study were placed in the participat-
ing facilities in Vancouver, Surrey, Abbotsford, and Quali-
cum Beach, British Columbia, 5−7 days before surveyor
arrival. We recruited consenting women who were
English-speaking, aged 19 to 49, and currently on MET or
BUP as OAT. Surveys were conducted as computer-
assisted personal interviews including a confidential audio-
computer-assisted self-entry interview portion for sensitive
questions. Answers were entered on a secured tablet with
trained medical student surveyors, and participants
received a $5 food/beverage gift card for their time. No
personal identifiers were collected. Study data were man-
aged using REDCap electronic data capture tools hosted
at the Child and Family Research Institute of British
Columbia.15
We collected general demographic information and details
of current MET or BUP use. Women reported their first,
most recent, and all methods of contraception ever used,
as well as patterns of use, reasons for non-use, and barriers
to accessing contraception.
We used descriptive statistics for characteristics of women
in our sample and for the subgroup of women at risk for
unintended pregnancy. To determine this subgroup, we
excluded those with the following conditions: no hetero-
sexual intercourse over the last 6 months, currently
Contraception Practices Among Women on Opioid Agonist Therapypregnant, unsure if pregnant, trying to get pregnant, meno-
pausal, or sterile. To understand pregnancy intention at the
time of conception among women who had been pregnant
within 5 years, we used the London Measure of Unplanned
Pregnancy, with a score of nine or less indicating an unin-
tended pregnancy.16
Ethics approval was received from the University of British
Columbia Research Ethics Board (#H14-00220) and Van-
couver Coastal Research Institute (#V14-00220), and
funding was provided by the College of Family Physicians
of Canada.RESULTS
Demographic Characteristics
Of the 156 women offered the survey, 133 consented to par-
ticipate (response rate 85.2%). Eighty participants (60%) met
the definition for currently being at risk of unintended preg-
nancy (Figure). Most participants were on MET (94%), self-
identified as white or Caucasian, and had a household
income less than $30 000 (Table 1). The mean age at first
intercourse was 14.6 years, with nearly half (65; 48.9%) indi-
cating first intercourse at 14 years or younger. The large
majority had experienced a prior birth (90.6%) or a prior
abortion (80.9%). Among 46 women who had a current
pregnancy or pregnancy within 5 years, 95.7% reported that
their most recent pregnancy was unintended.16 The average
age of first pregnancy was 18.7 years.Figure. Subset of women at risk for unintended pregnancy.Contraceptive Methods
We analyzed use of contraception among the 80 women at
risk for unintended pregnancy. As illustrated in Table 2,
participants were able to select more than one contracep-
tion method used at last intercourse; we report the most
effective method used based on current effectiveness
rates.17 We found the most effective method used at last
intercourse was “no method” (28.8%), followed by male
condom (16.3%) and injectable depo-medroxyprogester-
one (12.5%; Table 2). Only 5% of women indicated use of
the most effective methods, either the levonorgestrel intra-
uterine contraceptive or copper intrauterine device (IUD).
Note that at the time of this survey, subdermal implants
were not available in Canada. In addition, 5% reported
using dual protection, defined by the World Health Organi-
zation as a barrier and either a hormonal method or an
IUD.18 This contrasts with the most commonly reported
first contraceptive methods ever used: 46.3% indicated
oral contraceptive pills (OCP), followed by the male con-
dom (38.6%).
The mean age of first contraception use was 15 years (stan-
dard deviation 2.3). When asked whether their first method
used was before, during, or after their first experience of
intercourse, one-fifth of participants, 16 (20%), indicated
before; a third, 24 (30%), during; and half, 39 (48.8%), after.
These proportions varied depending on the selected contra-
ception method; of the 37 women who selected OCP, most
started after (21; 56.8%) first intercourse. However, for the000 JOGC 000 2020  3
Table 1. Baseline characteristics of study participants
No. (%) of participantsa
Characteristics All; n = 133
Women at risk of unintended
pregnancy; n = 80
Therapy
Methadone 125 (94.0) 74 (92.5)
Buprenorphine/naloxone 8 (6.0) 6 (7.5)
Age, mean § SD, y 34.3 § 8.2 30.8 § 7.5
Age group, y
≤25 19 (14.3) 16 (20.0)
>25−30 29 (21.8) 21 (26.3)
>30−35 27 (20.3) 20 (25.0)
>35−40 18 (13.5) 7 (8.8)
>40−45 22 (16.5) 9 (11.3)
>45 18 (13.5) 7 (8.8)
Data collection setting
Full-scope primary care (2 sites) 91 (68.4) 54 (67.5)
Methadone clinic (1 site) 20 (15.0) 15 (18.8)
Pharmacies (2 sites) 15 (11.3) 8 (10.0)
Women’s shelter (1 site) 9 (6.8) 3 (3.8)
Age at first intercourse, y
<12 4 (3.0) 3 (3.8)
12−14 61 (45.9) 47 (58.8)
15−17 58 (43.6) 26 (32.5)
18−20 9 (6.8) 4 (5.0)
>21 1 (0.75) 1 (1.3)
Mean § SD age 14.6 § 2.4 14.2 § 2.2
Median age 15 14
Gestational information
Any prior pregnancy 120 (90.2) 71 (88.8)
Mean § SD no. of pregnancies 3.7 § 2.3 3.6 § 2.3
Median no. of pregnancies 3 3
At least 1 prior birth 90 (67.7) 46 (57.5)
Mean § SD no. of births 2.3 § 1.5 2.1 § 1.5
Median no. of births 2 2
Any prior abortion 108 (81.2) 72 (90.0)
Mean § SD no. of abortions 1.9 § 1.1 1.9 § 1.1
Median no. of abortions 2 2
Racial/ethnic backgroundb
White 103 (77.4) 65 (81.3)
Aboriginal 32 (24.1) 15 (18.8)
Black 3 (2.3) 1 (1.3)
Other 9 (6.8) 5 (6.3)
Marital status
Single, never married 59 (44.4) 37 (46.3)
Living with partner/common-law 39 (29.3) 28 (35.0)
Divorced or separated 23 (17.3) 7 (8.8)
Married 7 (5.3) 5 (6.3)
Widowed 5 (3.8) 3 (3.8)
aUnless otherwise specified.
bCan identify with more than one.
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Table 2. Contraception practices (n = 80)
No. (%) of participants
Method
First method
ever used
Method used at
last intercourse
Most effective
method used at
last intercourse
Tubal ligation/sterilization 0 9 (11.3) 9 (11.3)
LNG-IUC 0 2 (2.5) 2 (2.5)
Copper IUD 1 (1.3) 2 (2.5) 2 (2.5)
DMPA 2 (2.5) 10 (12.5) 10 (12.5)
Birth control pill 37 (46.3) 9 (11.3) 9 (11.3)
Contraceptive patch 0 0 0
Contraceptive ring 1 (1.3) 0 0
Male condom 31 (38.8) 17 (21.3) 13 (16.3)
Emergency contraception 1 (1.3) 0 0
Withdrawal/pulling out 5 (6.3) 13 (16.3) 12 (15.0)
No method 2 (2.5) 23 (28.8) 23 (28.8)
Partner vasectomy 0 2 (2.5) 2 (2.5)
DMPA: depo-medroxyprogesterone; IUD: intrauterine device; LNG-IUC: levonorgestrel intrauterine contraceptive.
Table 3. Reasons for not using a method among women
at risk for unintended pregnancy (n = 23)
Reason selecteda No. (%) of participants
Don’t care/don’t worry/never got pregnant
before
9 (39.1)
Forgot to use 3 (13.0)
Don’t like contraception/unsatisfactory/side
effects
3 (13.0)
Breastfeeding 2 (8.7)
Partner or I are subfertile/infertile 2 (8.7)
Partner doesn’t like/won’t use 2 (8.7)
Leave to chance/fate when to have babies 1 (4.3)
Religious objection 1 (4.3)
Worried about weight gain 0
Contraception is too expensive/can’t afford 0
Don’t know 1 (4.3)
Other 4 (17.4)
aParticipants able to choose >1 reason.
Contraception Practices Among Women on Opioid Agonist Therapymale condom, most (19; 61.3%) used the contraceptive dur-
ing their first intercourse. Note that only 2.5% of women
reported dual protection at first intercourse.Reasons for Contraception Non-Use
Among those who indicated “no method” used during
their last intercourse (Table 3), the most commonly cited
response was “don’t care/don’t worry/never got pregnant
before.” Optional comments provided included “living onstreets hard to keep appointments” and “no period on
methadone.”Barriers to Contraception Use
When asked “In the past 12 months, did you ever expe-
rience any difficulties getting methods you wanted to
try?” and “In the past 12 months, did you ever experi-
ence any difficulties getting access to a health profes-
sional to provide a method you needed?” most (59;
73.8%) women indicated they had no difficulty. Of the
21 who did have difficulty, most (15; 71.4%) cited cost,
and four (19%) indicated they did not know where to
get the method. We asked participants to respond to the
following statement: “In the last 12 months, cost has
stopped me from using a method I wanted to use.”
Nearly half of respondents (39; 48.8%) “agreed or
strongly agreed” with this statement.
We found that the majority of women (58; 72.5%) indi-
cated no difficulty accessing a health care professional
(Table 4). Of those who reported difficulty, most partici-
pants cited transportation problems (12; 54.5%), followed
by in-office waiting (8; 40.9%) and cost (8; 36.4%). Of the
four respondents who indicated “other,” recorded answers
included “high on drugs,” “lack of communication,” and
“doctor refused to put in IUD after appointment had been
made.” We also found 70.7% of those in our sample felt
most comfortable receiving contraceptive advice from a
family physician, among the range of health professionals.
Table 4. Comfort with obtaining contraception from health care professionals (n = 133)
No. (%) of participants answering “yes” to
Health care professional
From which of the
following health professionals
would you feel comfortable getting
contraceptive advice and family
planning services?
From which of these
professionals would you feel
most comfortable getting
contraceptive advice and
family planning services?
Family doctor 129 (97.0) 94 (70.7)
Specialist doctor 103 (77.4) 7 (5.3)
Nurse practitioner 97 (72.9) 8 (6.0)
Public health nurse 93 (69.9) 6 (4.5)
Pharmacist 78 (58.6) 2 (1.5)
Midwife 63 (47.3) 1 (0.75)
School nurse 51 (38.3) 0
Other, don’t know, or no answer 3 (2.3) 5 (3.8)
WOMEN’S HEALTH  SANTÉ DES FEMMESDISCUSSION
We found that women at risk for unintended pregnancy used
the least effective contraceptive methods available at last inter-
course. Almost one-third indicated “no method,” followed by
the male condom and “withdrawal/pulling out.”Examination
of reasons for non-use revealed that 40% of this subset
selected “don’t care/don’t worry/never got pregnant before,”
even though the large majority of respondents indicated previ-
ous unintended pregnancies and therapeutic abortions.
Almost all (95.7%) women who had been pregnant in the
past 5 years indicated that their most recent pregnancy was
unintended. Less than 5% of respondents were on effective,
long-acting, reversible contraceptives, and only 5% reported
using dual protection. Most women indicated geographic or
time limitations and cost as the key barriers to accessing health
care professionals. Cost appeared to have a greater impact on
access to contraception methods, as indicated by nearly half
of the study group. This was supported by our finding that
78% were supported by a government-sponsored medication
plan. Women who indicated cost as a barrier to care may have
been referring to the direct costs (i.e., purchasing contracep-
tion) or indirect costs (i.e., travel, lost income, or childcare).
Our findings on the unmet need and paucity of contracep-
tion use among women using OAT greatly contrast with
the same descriptors of the general Canadian population,
as found by Black et al.19 Among contraception users, the
most common methods used by Canadian women were
condoms, OCP, and withdrawal at 54%, 44%, and 12%,
respectively.19 This trend is supported by recent Canadian
survey data.20 Black et al. found that only 15% of women
did not use contraception, contrasting with nearly double
that proportion (29%) in our study population.These findings support studies that have shown that
women with substance use disorders are less likely to use
contraception.1,21 Our demographic data point towards
some of the socioeconomic differences between our study
group and the general population. These include an earlier
age of first intercourse (14.6 years) and pregnancy (18.7
years) and a high incidence of abortion. In the general pop-
ulation, 31% of Canadian women at the time of meno-
pause will have had an abortion; yet our study shows that
among women using OAT, 80.7% had already had an
abortion.22 We found that recent pregnancies were over-
whelmingly (95.7%) unintended. The concurrent Canadian
Sexual Health Survey study found only 45% of BC women
reported that their most recent pregnancy was
unintended.12
In BC, OAT providers are not required to provide other
areas of primary care and may focus their practice on
addiction management. Encouraging providers to incorpo-
rate women’s health services may help mitigate this chal-
lenge. This is supported by studies that show improved
maternal mental health among women receiving reproduc-
tive services from drug treatment centres.23 On a public
health level, early contraception education and financial
support may improve contraception uptake, particularly
among OAT patients.
Limitations to our study include participant selection and
reporting bias. Recruitment was dependent on facilities
being willing to allow our surveyors to recruit among their
clients, thus selecting for sites motivated to understand
their patients’ contraceptive practices. Although over 20
facilities were approached, only six sites agreed to partici-
pate. We did not collect data on their reasons for choosing
Contraception Practices Among Women on Opioid Agonist Therapyor declining to participate. We attempted to include women
accessing a wide range of services by recruiting at clinics
prescribing OAT, as well as dispensing pharmacies and
community service locations. A strength of the study is the
distribution of recruitment sites throughout the majority of
the five provincial health authorities, which oversee health
care delivery based on geographical boundaries. Respond-
ents were self-selected based on their willingness to partici-
pate in a survey that asked sensitive questions; however,
our high participation rate minimizes self-selection bias.
Our findings may be a conservative estimate of the unmet
needs of women on OAT; most study participants were
recruited from clinics that provide comprehensive primary
care.CONCLUSION
We present the first Canadian data on the unmet need for
contraception, prevalence of unintended pregnancy, and con-
traception practices of women on MET or BUP therapy for
opioid use disorder. Despite the many contraceptive options
available, most women at risk for unintended pregnancy
choose the least effective methods, with no method used at
last intercourse being the most common response. Screening
for women’s health concerns, particularly an unmet need for
contraception, should be incorporated into substance use
treatment settings, postpartum obstetric services, and pri-
mary care clinics that provide opioid agonist therapy. Public
health initiatives to improve early contraception education
and method accessibility and reduce cost may also improve
uptake of contraception. Further research on the socioeco-
nomic barriers to reproductive care and impact of unin-
tended pregnancy will allow us to better understand the
unique concerns of this patient population.REFERENCES
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